Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Chemical pathology Stories

2014-01-13 08:28:33

The company's SnapPath® system facilitates personalized medicine MOUNTAIN VIEW, Calif., Jan. 13, 2014 /PRNewswire/ -- Based on its recent analysis of the cancer diagnostics market, Frost & Sullivan recognizes BioMarker Strategies LLC with the 2013 North American Frost & Sullivan Award for Technology Innovation Leadership. BioMarker Strategies has pioneered the development and validation of SnapPath®, a novel platform for live tumor cell processing and testing. This rapid, robust and...

2014-01-13 04:21:04

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ -- Study supported by a EUR3.5 million IWT grant from the Flemish Government arGEN-X, a clinical stage human therapeutic antibody company, announces that it has advanced ARGX-110, a novel anti-CD70 antibody, into the safety and efficacy expansion part of its Phase Ib study. The objective is to further investigate the safety of ARGX-110 in CD70-positive cancer patients with either...

2014-01-13 00:22:35

The NBDA Intends to Change the Dismal Success Rate of Biomarkers by Creating Evidence Based, End-to-End Biomarker Development Processes A Collaborative Network-Based, Non-Profit Organization, the NBDA Will Create Standards to Successfully Develop Biomarkers Needed for Precision (personalized) Medicine WASHINGTON, Jan. 13, 2014 /PRNewswire-USNewswire/ -- The launch of a new independent, non-profit organization, the National Biomarker Development Alliance (NBDA), broadly engaging...

2014-01-07 08:30:19

SCCM Event Examines Groundbreaking AKI Risk Assessment Biomarkers SAN DIEGO, Jan. 7, 2014 /PRNewswire/ -- An international panel of critical care experts will discuss how new biomarkers for risk assessment of acute kidney injury (AKI) could affect care of critically ill patients at a symposium being held in conjunction with the Society of Critical Care Medicine (SCCM) 43rd Critical Care Congress in San Francisco, Calif. Astute Medical, Inc. is sponsoring the event "Early AKI Assessment: Are...

2013-12-31 08:22:46

Following the Successful Utilization of A3 Adenosine Receptor Biomarker in Can-Fite's Phase IIb Rheumatoid Arthritis Study PETACH TIKVA, Israel, Dec. 31, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the following: The Company's subsidiary, OphthaliX Inc. (OTCQB: OPLI), will conduct a retrospective analysis...

2013-12-23 12:22:14

DUBLIN, Ireland, December 23, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/ffpj56/chromatography) has announced the addition of the "2013 Report on the International Chromatography Reagents Market - Includes Forecasts to 2018" [http://www.researchandmarkets.com/research/ffpj56/chromatography ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Various government...

2013-12-19 08:26:39

PETACH TIKVA, Israel, Dec. 19, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today, that the U.S. Patent and Trademark Office granted the Company a patent which bears the Patent No. 8,541,182 and is titled "A Biological Marker for Inflammation". The patent was granted on September 24, 2013 and will be valid until 2026,...

2013-12-18 13:24:08

Measuring changes in certain proteins -- called biomarkers -- in people with amyotrophic lateral sclerosis may better predict the progression of the disease, according to scientists at Penn State College of Medicine. ALS is often referred to as Lou Gehrig's disease, is a neurological disease in which the brain loses its ability to control movement as motor neurons degenerate. The course of the disease varies, with survival ranging from months to decades. "The cause of most cases of ALS...

2013-12-18 12:27:00

DUBLIN, Dec. 18, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/8tn4zn/biomarker) has announced the addition of the "Biomarker Partnering Terms and Agreements" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare...

2013-12-18 12:22:02

Mass Detector for Chromatography Receives First Annual Analytical Scientist Magazine Innovation Award MILFORD, Mass., Dec. 18, 2013 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announced today that its ACQUITY(®) QDa((TM)) Detector was ranked among the top innovations of 2013 by The Analytical Scientist magazine. (Logo: http://photos.prnewswire.com/prnh/20110707/NE31586LOGO ) Introduced on October 7, 2013, the ACQUITY QDa Detector is a small, easy-to-use and affordable mass...